Objective: To observe the effect and mechanism of Garlicin in treating coronary heart disease (CHD) with angina pectoris. Methods: Clinical study: 55 patients were selected and randomized into the Garlicin group and the nitroglycerin group. To Garlicin group, 60 mg of Garlicin was given by adding in 5% glucose solution for intravenous dripping once per day, the therapeutic course was 10 days. The symptoms, taking of nitroglycerin, ECG, granular membrane protein-140 (GMP-140, by ELISA) in activated platelet, plasma endothelin (ET, by RIA),and microcirculation before and after treatment were observed. Experimental study: (1) Contrast examination of coronary artery was conducted with meglucamine diatrizoate before and after administration of Garlicin to measure the diameter of the left anterior descending branch and the left circumflex branch of coronary artery and the dilatation rate of them were calculated. Moreover, to the coronary spasm model made by iv dripping of pituitrin, the normal saline, garlicin, puerarin and nitroglycerin were administered separately, and the coronary dilatation rate after administration were measured. (2) Ischemia/reperfusion model of isolated rabbits' heart was established and divided into the blank control, pre-treated, Garlicin, polymyxin B, and Garlicin plus polymyxin B groups, the size of infarcted myocardium in each groups was measured. Results: The effective rate in Garlicin group on anginal symptom and ECG was 82.4% and 59.3% respectively and those in the nitroglycerin group was 69.3% and 38.5% respectively. The CMP-140 level lowered significantly after Garlicin administration. And Garlicin showed a significant dilating effect on coronary artery of dog with no significant difference to that of nitroglycerin. Conclusion: Garlicin has obvious prevention on coronary ischemia, can reduce the scope of myocardial infarction, the effective condition of relapse. Results: The treatment of all the 35 women was successful. The recovery duration of serum β-HCG, disappearance duration of TP sac and existent time of peritoneal fluid in the treated group were 20.0±7.8 days, 1.2±0.7 months and 10.7±2.9 days respectively, which were significantly different from those in the control group (24. 4±8.1 days, 3.6±1.7 months and 19.1±3.2 days respectively(P＜0.05, P＜0.01 and P＜0.05 respectively), but the existent time of fetal cardiac beat in the two groups (8.8±1.9 days vs 9.0±1.3 days) was not significantly different (P＞0.05). The post-treatment oviduct obstructive rate in the two groups was 10.5% and 43.8% respectively, that in the treatment group was less significant (P0.05).Conclusion: The two therapies (IMI alone and IMI combined with EP2) could obtain equal efficacy in curing TP. Compared with IMI alone, the combined therapy appears to have the effects of accelerating the resorption of gestational sac and peritoneal fluid, improving the patency of fallopian tube and ameliorating the circumstance of pregnancy, which is favorable to improvement of the re-pregnancy rate and reduction of the re-occurrence of ectopic pregnancy as well as to the enhancement of the effect of IMI in killing trophocytes. But there is not enough proof to show the potency of EP2 in killing embryo.